An elderly patient with advanced small cell lung cancer who had a history of smoking and who had previously had tuberculosis and chronic kidney disease relapsed after classical treatment with etoposide combined with carboplatin.
Methods:
The patient was given chemotherapy again, with albumin-bound paclitaxel, etoposide capsules, apatinib, and other treatment. The last medication was apatinib.
Results:
After treatment with anlotinib, the patient has survived for 15 months with good quality of life.
Conclusion:
This is the first report on the precise efficacy of anlotinib in the treatment of advanced small cell lung cancer. Anlotinib is an important option for patients with small cell lung cancer.
XieCWanXQuanH, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci2018; 109: 1207–1219.
2.
GasparLEMcNamaraEJGayEG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer2012; 13: 115–122.
3.
NicholsonAGChanskyKCrowleyJ, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol2016; 11: 300–311.
4.
SabariJKLokBHLairdJH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol2017; 14: 549–561.
5.
RossiADi MaioMChiodiniP, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol2012; 30: 1692–1698.
6.
HornLMansfieldASSzczęsnaA, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med2018; 379: 2220–2229.
7.
HanahanDWeinbergRA.Hallmarks of cancer: the next generation. Cell2011; 144: 646–674.
8.
GuoshuangSFangchaoZDengfengR, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol2018; 11: 120.
9.
ZhouHBinmadiNOYangYH, et al. Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis2012; 15: 391–407.
10.
XieCWanXQuanH, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci2018; 109: 1207–1219.
